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Sllmmary 
CIITA (a major histocompatibility complex [MHC] class II transactivator) has been shown to 
be required for the expression  of MHC class II genes in both B cells and interferon y-inducible 
cells. Here we demonstrate that CIITA not only activates  MHC class II genes but also genes 
required for antigen presentation. Mutant HeLa cells, defective in the expression of classic MHC 
class II genes, invariant chain, and the newly described human histocompatibility  leukocyte antigen- 
DM genes, were used to study the role of CIITA in the regulation of these genes. Upon transfec- 
tion with CIITA cDNA, the mutant cells expressed  all three genes,  suggesting that CIITA is 
a global regulator for the expression  of genes  involved in antigen presentation. 
C 
lass II  transactivator  (CIITA)  has  initially been  iso- 
lated and characterized as a transcriptional coactivator 
for the expression  of MHC class II genes (1). CIITA is also 
necessary and sufficient for the IFN-3,-inducible expression 
of  class II genes (2, 3). The expression of CIITA itself  is IFN-3, 
inducible, and its induction does not require de novo protein 
synthesis (2, 3). We have also demonstrated that the tyrosine 
kinase JAK1 is required for the transcription of the CIITA 
gene after IFN-'y stimulation (2). Although CIITA activates 
the transcription of class II genes, it does not seem to have 
DNA-binding activity, suggesting that it may act through 
other DNA-binding proteins (1). 
To serve as APC to CD4 T  cells, cells must express not 
only MHC class II molecules on the cell surface, but also 
genes necessary for antigen processing and presentation, in- 
cluding the invariant chain (Ii) and the newly described HLA- 
DM molecules, which are distant evolutionary homologs of 
HLA-D genes (4-7). The promoter structure and the regu- 
lation of transcription of the MHC class II genes and the 
Ii genes are similar,  and they share common regulatory c/s- 
acting DNA elements (8). Although the regulation of HLA- 
DM is not yet well understood, the promoter structure of 
DM genes is similar to that of class II genes, suggesting that 
they may share common regulatory factors for their expres- 
sion (4). In addition, the expression of HLA-DM is restricted 
to APC and it is also IFN-3' inducible. Therefore, it is rea- 
sonable to speculate that CIITA may regulate not only the 
classic MHC class II genes but also Ii and DM genes.  To 
test this hypothesis, we used mutant cells which were iso- 
lated and characterized previously (9). 
Materials and Methods 
Ceil Culture  All cell lines used were maintained  in DMEM sup- 
plemented with 10% fetal bovine serum and 2 mM glutamine. 
Human IFN-"/(gift from Biogen, Cambridge, MA) was used at 
a concentration of 500 U/ml. 
Transfections.  Mutant  cells were cotransfected with  CIITA 
cDNA or JAK1 cDNA along with the hygromycin gene via the 
calcium phosphate method. 2 d after transfection, cells were split 
1:2 into medium containing 400 #g of hygromycin (Calbiochem 
Corp., La  Jolla, CA). BLS-2  cells were transiently transfected  with 
either control DNA or CIITA cDNA. Cells were harvested 2 d 
after transfection and RNA was analyzed. 
Flow CytometryAnalysis.  Cells  were stained for HLA-DR sur- 
face expression with L243, and secondary staining was performed 
with PE-conjugated  goat anti-mouse IgG (Southern  Biotechnology 
Associates, Birmingham, AL). The stained  cells were analyzed  with 
FACStar (Becton Dickinson & Co., Mountain View, CA). 
PCR.  RNA preparation, cDNA synthesis, and PCIL  condi- 
tion were described previously (2). Sequences of oligonucleotides 
for primers used in PCR amplification are as follows: Ii sense, 
TCCCAAGCCTGTGAGCAAGATG;  Ii antisense, CCAGTTCCA- 
GTGACTCTTTCG; DMB sense, TCCTTCAACAAGGATCTG- 
CTG; DMB  antisense, CTTCCTCCACGTGATAGTCAC. The 
primer sequences for HLA-DR and actin genes were as described 
(2). Procedures used for lysis, electrophoresis, and blotting were 
described previously (10). Each lane contained 106 cell equivalent 
amount of protein. 
Results and Discussion 
The mutant HeLa ceils that we used are defective in the 
tyrosine kinase JAK1, which is necessary for IFN signaling. 
Consequently they do not express  most IFN-3,-inducible 
genes, including class II genes (9).  It has been shown that 
the transfection ofJAK1 cDNA can rescue the IFN-3r-respon- 
sive phenotype (10; Fig. 1). In addition, we have also demon- 
strated that the transfection of CIITA cDNA activates  the 
expression of MHC class II genes even before IFN-3' induc- 
tion, suggesting that CIITA is both necessary and sufficient 
for the expression  of MHC class II genes, and furthermore, 
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Figure  1.  Cell surface  expression  of MHC class II molecules. Cells were 
untreated  (open profile) or treated (shaded  profile) with human IFN-'y at 
500 U/ml for 2 d and analyzed by flow cytofluorimetry for the expression 
of HLA-DR. 
that the constitutive expression of CIITA can bypass the re- 
quirement  for the tyrosine kinase JAK1  (2;  Fig.  1).  There- 
fore, we used these mutant cells to examine whether CIITA 
plays a  role in  the regulation  of genes  involved in  antigen 
presentation.  As shown in Fig. 2 a, mutant HeLa cells, E2A4, 
do not express HLA-DR,  Ii, or HLA-DM genes even after 
IFN-3' treatment.  However, CIITA-transfected mutant cells 
show a high basal level of transcripts for both Ii and HLA- 
DM  before  IFN-'y treatment,  and  as expected,  the level is 
not further enhanced after IFN-3, treatment because CIITA 
cDNA is expressed under the control of a constitutive pro- 
moter in these transfectants.  Ii and HLA-DM transcripts in 
wild-type HeLa cells and JAKl-transfected mutant  cells are 
inducible upon IFN-q, stimulation.  There is, however, a basal 
level of HLA-DM  expression  in  uninduced  wild-type  and 
JAKl-transfected mutant HeLa cells that is not detectable in 
the mutant  cells,  suggesting  that JAK1  is also required  for 
this (Fig. 2 a). This may reflect additional transcriptional con- 
Figure  3.  The expression  of HLA-DR, Ii, and HLA-DM genes  in BLS-2 
cells and BLS-2 cells transfected with CIITA. Control lane has the same 
components as others except that it does not have the first-strand product. 
The data are representative of three independent analyses. 
trois used for HLA-DM but not Ii or HLA-DR, or alterna- 
tively there is a low basal level of CIITA, and HLA-DM may 
have a  greater  sensitivity  to  transactivation. 
To determine the level of HLAoDM protein, Western blot 
analysis was performed.  In agreement with the RNA data, 
mutant HeLa cells have no detectable HLA-DM protein, but 
cells transfected with CIITA cDNA show constitutive-level 
HLA-DM protein  (Fig.  2  b, lanes 3-6).  In contrast,  HeLa 
cells show normal inducible expression of HLA-DM protein 
(Fig.  2  b,  lanes  I  and  2). 
We also  tested  the effect of CIITA on  the expression  of 
both  Ii and  HLAoDM genes with  BLS-2 cells.  BLS-2 cells 
have been shown to have a defective CIITA gene, which results 
in the lack of MHC class II gene expression (1). As predicted 
from the HeLa cell results, HLA-DM expression is increased 
drastically in  cells transfected  with  CIITA cDNA.  Ii tran- 
Figure  2.  The  expression  of 
HLA-DR, Ii, and HLA-DM mole- 
cules by CIITA. (a) The expression 
of HLA-DRA, li, and HLA-DMB 
genes in mutant cells and in trans- 
fected cells with  either JAK1  or 
CIITA. Cells were harvested after 
2 d of incubation either with (+) 
or without (-) human IFN-3, at 
500 U/ml in the medium. The data 
are representative  of three indepen- 
dent  analyses. (b)  Expression of 
HLA-DMB protein in mutant cells 
and mutant  cells transfected with 
CIITA. Whole cell lysates  from cells 
were subjected  to SDS-PAGE, trans- 
ferred to  nitrocellulose filter, and 
probed with an antiserum  to human 
HLA-DMB subunit. Raji cells are 
MHC  class II positive human  B 
lymphoblastoid cells. 
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duced after transfection with CIITA (Fig. 3). Similarly, a low 
basal level of HLA-DK transcripts are present in BLS-2 cells, 
although the level is greatly increased in BLS-2 cells trans- 
fected with the CIITA gene or human B cells (Fig.  3). 
We have shown here that CIITA regulates not only MHC 
class II genes but also the Ii and HLA-DM genes, which are 
absolutely required for antigen presentation. CIITA, there- 
fore,  seems to have a global role in the regulation of genes 
that participate in antigen presentation. It is not clear why 
CIITA-defective BLS-2 cells have residual-level transcripts for 
HLA-DK, Ii, and HLA-DM genes.  It is possible  that the 
mutated form of CIITA molecule in BLS-2 cells may have 
residual transactivational  function, but the efficiency of trans- 
activation is in any event greatly reduced. Our study with 
mutant HeLa cells, however,  clearly demonstrates that the 
expression  of Ii and HLA-DM genes in addition to HLA- 
DR genes is coregulated by CIITA upon IFN-3' induction. 
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